Avandia Survives Scrutiny From FDA Panel

Law360, New York (July 31, 2007, 12:00 AM EDT) -- After a contentious day of hearings, a panel of U.S. Food and Drug Administration advisers has overwhelmingly voted to keep Avandia on the market despite data that suggests the controversial diabetes drug leads to more cardiovascular risks.

On Tuesday, the FDA panel voted 22 to 1 to recommend that GlaxoSmithKline's Avandia remain on the market, setting aside widespread outcry from consumers and medical professionals that the medication is unsafe.

While the panel acknowledged that evidence did show an increased risk of heart attack in some Avandia...
To view the full article, register now.

Law360 UK

UK Financial Services

Read Our Latest UK Legal News & Analysis

Financial Services Law360 UK and Insurance Law360 UK provide breaking news and in-depth analysis on U.K. and European Union regulation, enforcement, legislation, and litigation involving banks, investment firms, insurers, and more.